Literature DB >> 2999259

Glycoproteins of human parainfluenza virus type 3: characterization and evaluation as a subunit vaccine.

R Ray, V E Brown, R W Compans.   

Abstract

The envelope glycoproteins of human parainfluenza type 3 virus were characterized by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and reactivity with specific monoclonal antibodies. The molecular weight of the hemagglutinin-neuraminidase (HN) glycoprotein was found to be 72,000, and the fusion (F) glycoprotein appeared to consist of 74,000 (F0) or 56,000 (F1) species. Envelope glycoproteins were solubilized with octyl-glucoside and, after removal of the detergent by dialysis, were used for immunization of hamsters. Other animals were immunized with a formalin-inactivated preparation of whole virus. A single subcutaneous immunization with these antigen preparations induced a serum antibody response to the HN and F glycoproteins, as determined by plaque neutralization, hemagglutination inhibition, inhibition of virus-induced cell fusion, and immune precipitation tests. An IgG antibody response to both glycoproteins was also observed in bronchial washings. Animals immunized with the highest dose of envelope glycoproteins showed complete protection from challenge infection, whereas immunization with inactivated virus did not completely protect animals.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2999259     DOI: 10.1093/infdis/152.6.1219

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

1.  Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity.

Authors:  M K Spriggs; B R Murphy; G A Prince; R A Olmsted; P L Collins
Journal:  J Virol       Date:  1987-11       Impact factor: 5.103

2.  Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees.

Authors:  M L Clements; R B Belshe; J King; F Newman; T U Westblom; E L Tierney; W T London; B R Murphy
Journal:  J Clin Microbiol       Date:  1991-06       Impact factor: 5.948

3.  Role of individual glycoproteins of human parainfluenza virus type 3 in the induction of a protective immune response.

Authors:  R Ray; B J Glaze; R W Compans
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

4.  Characterization of a live, attenuated human parainfluenza type 3 virus candidate vaccine strain.

Authors:  R Ray; K Meyer; F K Newman; R B Belshe
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

5.  Association of the parainfluenza virus fusion and hemagglutinin-neuraminidase glycoproteins on cell surfaces.

Authors:  Q Yao; X Hu; R W Compans
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

Review 6.  Current approaches to the development of vaccines effective against parainfluenza viruses.

Authors:  B R Murphy
Journal:  Bull World Health Organ       Date:  1988       Impact factor: 9.408

7.  Temperature-sensitive phenotype of the human parainfluenza virus type 3 candidate vaccine strain (cp45) correlates with a defect in the L gene.

Authors:  R Ray; M S Galinski; B R Heminway; K Meyer; F K Newman; R B Belshe
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

Review 8.  Parainfluenza viruses.

Authors:  Kelly J Henrickson
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

9.  Immune responses to plasmid DNA encoding the hepatitis C virus core protein.

Authors:  L M Lagging; K Meyer; D Hoft; M Houghton; R B Belshe; R Ray
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

10.  Development of oligomannose-coated liposome-based nasal vaccine against human parainfluenza virus type 3.

Authors:  Kyosuke Senchi; Satoko Matsunaga; Hideki Hasegawa; Hirokazu Kimura; Akihide Ryo
Journal:  Front Microbiol       Date:  2013-11-26       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.